These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 22845401

  • 21. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
    Amano R, Yamada N, Noda E, Kubo N, Tanaka H, Muguruma K, Takashima T, Yashiro M, Maeda K, Onoda N, Sawada T, Nakata B, Ohira M, Ishikawa T, Hirakawa K.
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
    [Abstract] [Full Text] [Related]

  • 22. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
    Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H.
    PLoS One; 2016 Nov; 11(1):e0146456. PubMed ID: 26745625
    [Abstract] [Full Text] [Related]

  • 23. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH, Song IH, Noh R, Kang HY, Kim SB, Ko SY, Lee ES, Kim SH, Lee BS, Kim AN, Chae HB, Kim HS, Lee TH, Kang YW, Lee JD, Lee HY.
    BMC Cancer; 2015 Apr 08; 15():236. PubMed ID: 25885683
    [Abstract] [Full Text] [Related]

  • 24. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
    Kim MJ, Choi JI, Lee JS, Park JW.
    J Gastroenterol Hepatol; 2011 Jul 08; 26(7):1201-6. PubMed ID: 21371120
    [Abstract] [Full Text] [Related]

  • 25. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
    Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten TM.
    Oncology; 2013 Jul 08; 84(1):6-13. PubMed ID: 23075905
    [Abstract] [Full Text] [Related]

  • 26. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M.
    Oncologist; 2009 Jan 08; 14(1):70-6. PubMed ID: 19144684
    [Abstract] [Full Text] [Related]

  • 27. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
    Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Cammà C, Colombo M, SOFIA (SOraFenib Italian Assessment) study group.
    Hepatology; 2011 Dec 08; 54(6):2055-63. PubMed ID: 21898496
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
    Song T, Zhang W, Wu Q, Kong D, Ma W.
    Eur J Gastroenterol Hepatol; 2011 Nov 08; 23(12):1233-8. PubMed ID: 21941188
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
    Miyahara K, Nouso K, Tomoda T, Kobayashi S, Hagihara H, Kuwaki K, Toshimori J, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K.
    J Gastroenterol Hepatol; 2011 Nov 08; 26(11):1604-11. PubMed ID: 22011296
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
    Raoul JL, Bruix J, Greten TF, Sherman M, Mazzaferro V, Hilgard P, Scherubl H, Scheulen ME, Germanidis G, Dominguez S, Ricci S, Nadel A, Moscovici M, Voliotis D, Llovet JM.
    J Hepatol; 2012 May 08; 56(5):1080-1088. PubMed ID: 22245896
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient.
    Di Lorenzo G, Imbimbo M, Leopardo D, Marciano R, Federico P, Buonerba C, Salvatore B, Marinelli A, Palmieri G.
    Int J Immunopathol Pharmacol; 2010 May 08; 23(3):951-4. PubMed ID: 20943068
    [Abstract] [Full Text] [Related]

  • 40. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
    Lee SJ, Lee J, Park SH, Park JO, Park YS, Kang WK, Lee J, Yim DS, Lim HY.
    Invest New Drugs; 2012 Aug 08; 30(4):1540-7. PubMed ID: 21695438
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.